In May 2025 the FDA released a draft guidance with a title that sounds bureaucratic and is in fact one of the most consequential documents of the decade for anyone who uses AI to build a dossier: "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products." It proposes a risk-based credibility-assessment framework for AI models whose output supports a regulatory decision, and as of this writing it sits in the comment-response window, which means the wording is not yet final and the people who file substantive comments are, in a real and literal sense, helping write the rule. This is the single highest-leverage moment a Level 5 leader will encounter in the regulatory-AI landscape, and most organizations will let it pass in silence, then spend a decade complying with language they could have shaped with a well-argued letter. This lesson is the craft of that letter, and of the broader discipline of public-consultation and workplan engagement across the FDA Dockets, the EMA public consultations, the MHRA AI Airlock, and the ICH Step-2 comment periods. The previous lesson built the standing; this lesson spends it, on the record, in the venues where a comment becomes a clause.

Why a Docket Comment Is the Highest-Leverage Act Available

A docket comment is the rare instrument in regulatory life that lets a single organization alter the text of a rule before that rule binds the entire industry, and the asymmetry of its leverage is what a Level 5 leader must internalize. The cost of a well-researched comment is measured in days of one expert's time; the value, if the comment moves a clause, is measured in the cumulative cost or savings across every AI-assisted submission the organization files for the next decade, multiplied across the industry. When the FDA proposes that an AI model supporting a regulatory decision must meet a credibility standard, the precise definition of "credibility," the granularity of the risk-based tiering, and the documentation the framework demands are all live, and a comment that names a specific operational problem with the draft wording is read by the very people deciding the final text. Silence in a comment window is not neutral; it is a forfeited clause, because the final guidance will be shaped by whoever did show up, which is usually a smaller and more self-interested set of voices than the industry as a whole.

The leverage is greatest precisely when the draft is most unsettled, which is exactly the state of the regulatory-AI landscape in 2026. The FDA May 2025 AI credibility-framework draft is in its comment-response window with finalization timing undetermined, the EMA is working through jurisdictional implementation of the 14 January 2026 FDA-EMA Guiding Principles with publication dates still on a moving workplan, and the ICH process is producing AI-adjacent guidance through its Step-2 public-comment stages. Every one of these is an open door, and the door does not stay open. A leader who treats public consultation as a core function rather than an occasional reaction builds the monitoring, the drafting capability, and the cross-functional review process that let the organization respond substantively to each window as it opens, instead of discovering the window after it has closed. The difference between an organization that shapes the rules and one that inherits them is, very often, simply whether someone was watching the dockets and ready to write.

The Anatomy of a Comment That Moves Guidance

A comment that changes a final guidance has a recognizable structure, and it is the opposite of the generic endorsement that fills most dockets and accomplishes nothing. It identifies the specific provision at issue by section number or line, so the agency reviewer can locate exactly what the comment addresses without hunting. It states the operational consequence of the current wording using the organization's real, concrete experience, because an agency drafting an implementable rule needs to know how the draft language actually behaves at the keyboard of a working medical writer or pharmacovigilance scientist. It proposes specific alternative wording rather than merely objecting, because a reviewer revising a document needs replacement text, not a complaint. And it grounds the proposal in a principle the agency has already endorsed, so the change reads as helping the agency achieve its own stated goal rather than as the commenter pursuing a private interest. A comment built this way gives the reviewer everything needed to adopt it: the location, the problem, the fix, and the justification in the agency's own terms.

The contrast makes the discipline concrete. A comment that says "we support the FDA's risk-based approach to AI" is noise; it occupies a docket entry and moves nothing, because it gives the reviewer no location, no problem, and no fix. A comment that says "the credibility-assessment framework in the draft, as written, appears to require a full re-establishment of model credibility on every model update, which is incompatible with the Predetermined Change Control Plan approach the agency finalized for AI-enabled device software functions in December 2024; we propose reconciling language that allows pre-specified modifications within an established credibility envelope, consistent with the PCCP framework" is signal, and signal is what gets incorporated. The second comment names the provision, states a real operational consequence, proposes specific wording, and ties it to a framework the agency itself built. It also does something subtler: it demonstrates that the commenter understands the agency's own body of work well enough to spot an internal inconsistency, which is exactly the credibility that makes a reviewer take the proposed fix seriously.

The FDA May 2025 Credibility-Framework Comment Cycle

The FDA May 2025 draft guidance is the worked example every life-sciences AI leader should study, because it is both live and directly consequential for AI-assisted submissions. The draft proposes a risk-based credibility-assessment framework: the rigor of the credibility evidence required for an AI model scales with the model's influence on the regulatory decision and the consequence of the model being wrong, which is the same risk-based logic that runs through the FDA-EMA Guiding Principles. For a sponsor using AI to draft or support content in a submission, the framework's definitions determine what evidence the organization will have to produce to defend its AI use, which makes the comment window a chance to ensure those evidentiary demands are implementable rather than aspirational. The leader's task is to read the draft not as a finished rule to prepare for but as a text to improve, identifying the provisions where the draft wording would impose an unworkable or disproportionate burden and proposing the reconciling language.

The substantive opportunities in this particular draft are specific and a leader should approach them with named alternatives. Where the draft's notion of model context of use is ambiguous about whether a generative model used for first-draft authoring with full human reconciliation sits at the same credibility tier as a model whose output feeds a decision unreviewed, a comment can propose that the framework distinguish AI that produces human-verified drafts from AI whose output is relied upon directly, because the named author's reconciliation is itself a credibility control. Where the framework's lifecycle-monitoring expectations could be read to demand re-validation incompatible with a Predetermined Change Control Plan, a comment can propose the reconciling envelope language. Where the documentation burden could be read to require disclosure that would expose commercial confidential information or trade secrets, a comment can propose a tiered-disclosure approach that satisfies transparency without forcing CCI into the public record. Each of these is a real provision, a real operational consequence, and a proposable fix, which is precisely the comment structure that moves a final guidance.

Navigating the FDA Dockets Mechanically

The mechanics of the FDA Dockets matter, because a brilliant comment filed after the window closes or against the wrong docket accomplishes nothing, and a Level 5 leader runs this as a managed process rather than an individual scramble. FDA draft guidances are published with a docket number and a comment period announced in the Federal Register, and comments are filed through the federal eRulemaking portal at regulations.gov, where each docket has its own page, its own deadline, and its own public comment record. The standard comment period for a draft guidance is commonly sixty days, sometimes extended, and the leader's monitoring function must track the opening and the deadline so the cross-functional drafting and review can complete before it closes. Comments filed to a docket become part of the public record, which is both an opportunity, the organization's position is on the record and citable, and a constraint, nothing in the comment can disclose confidential information the organization is not prepared to make public.

The internal process is what separates an organization that comments well from one that comments late or not at all. A defensible commenting process has a named owner, typically the Head of AI for Regulatory working with regulatory intelligence, who watches the dockets and triggers a drafting workstream the moment a relevant window opens. The draft comment is built by the experts who actually run the affected workflow, reviewed by legal for confidential-information exposure and by the regulatory function for strategic alignment, and approved at the level appropriate to a public, on-the-record organizational position. The comment is filed before the deadline with margin, logged in the engagement record as an asset, and coordinated with the industry consortia so the organization's position is amplified by aligned bodies such as those convened through DIA, RAPS, TransCelerate, and PHUSE rather than contradicted by them. Run this way, commenting is a repeatable capability, not a heroic one-off, and the organization is ready for every window rather than surprised by each.

EMA Consultations, the MHRA AI Airlock, and ICH Step-2

The European and international channels each have their own character, and a leader with a global portfolio must engage all of them in the register each one rewards. The EMA runs public consultations on draft guidelines, reflection-paper revisions, and the workstreams of its multi-year AI Workplan, and the European process leans heavily on written consultation responses and multi-stakeholder workshops, which means influence is exercised through a well-argued response that names the unworkable clause and proposes implementable wording, often aggregated through industry bodies. The EMA Workplan is itself a roadmap of what European expectations will become, and each of its workstreams, the responsible-AI principles, the terminology guide, the change-management strategy, is a place where industry input is actively sought before the expectation hardens into guideline. The leader treats an EMA consultation response as a strategic deliverable built to the same standard as an FDA comment: specific provision, real operational consequence, concrete alternative, grounding in an EMA-endorsed principle.

The MHRA AI Airlock and the ICH Step-2 comment periods complete the map and each carries a distinct strategic value. The MHRA AI Airlock is a regulatory sandbox that produces published findings on the hard problems of AI regulation, synthetic-data validation, explainability, and hallucination handling, and even a sponsor whose primary AI use is submission drafting rather than device software gains by studying its published outputs to anticipate the controls the FDA and EMA will eventually expect, because good ideas migrate across the regulators. The ICH Step-2 comment period is the highest-leverage international window of all, because ICH guidelines, once finalized, are adopted across every ICH region at once, so a comment that shapes an ICH guideline at Step-2 shapes the rule in the United States, Europe, Japan, and beyond simultaneously, a return on a single well-written comment that no national docket can match. The leader monitors the ICH Step-2 windows with particular attention, because the multiplier on a successful ICH comment is the largest available anywhere in the system.

From Comment to Coalition to Closed Loop

A single organization's comment is louder when it is part of a coordinated chorus, and the leader's advocacy strategy extends beyond filing the organization's own letter to shaping the aligned positions of the bodies that aggregate industry voice. When DIA, RAPS, TransCelerate, PHUSE, or a body like EFPIA in Europe develops a consolidated position on a draft guidance, the organization's individual comment and the consortium's aggregated comment reinforce each other, and a reviewer reading a specific operational concern in the company's letter and the same concern echoed in a multi-company position gives that concern weight that no single voice carries. The leader coordinates the timing and the substance so the organization's comment and the consortium positions it contributes to point the same direction, which is the difference between a chorus and a cacophony. This is where the standing built in the previous lesson, the relationships in the societies and the contributions to the consortia, converts directly into amplified influence at the comment window.

The discipline closes, as every Level 5 discipline does, with the loop back into the enterprise, because engagement that does not change what the organization does is theater a regulator will eventually notice. When a comment cycle reveals that the agency is converging on a particular evidentiary expectation, that expectation becomes a requirement in the organization's validation framework before the guidance finalizes, so the organization is building the controls the rule will require while the rule is still being written. When the FDA credibility framework finalizes, the organization that commented substantively is not retrofitting; it has been operating against the framework's logic for the months or years the comment cycle ran, and its AI use is already defensible against the new text. The engagement record, every comment filed, every consortium position contributed to, every expectation looped back into a control, is itself the asset that answers an inspector, a board, or a Day 74 Information Request asking how the organization governs its AI. The leader who runs public consultation this way is not subject to the rules; the leader is, in the most literal and documented sense, one of their authors, which is exactly the posture the final lesson of this program will ask you to operationalize into a concrete plan.

Key Takeaways

• A docket comment is the highest-leverage act in regulatory life: days of one expert's time can alter a clause that binds every AI-assisted submission for a decade. The FDA May 2025 draft "Considerations for the Use of AI to Support Regulatory Decision-Making" sits in its comment-response window with finalization timing undetermined, the EMA is working through implementation of the 14 January 2026 FDA-EMA Guiding Principles, and ICH produces AI-adjacent guidance at Step-2. Silence in a comment window is a forfeited clause, because the final text is shaped by whoever showed up.
• A comment that moves guidance names the specific provision, states the real operational consequence, proposes concrete alternative wording, and grounds the proposal in a principle the agency already endorsed. "We support the risk-based approach" is noise; "the credibility framework as drafted appears to require re-establishing credibility on every model update, incompatible with the December 2024 PCCP framework, and we propose this reconciling envelope language" is signal that gets incorporated and demonstrates the commenter understands the agency's own body of work.
• The FDA May 2025 credibility-framework draft offers specific, proposable opportunities a leader should approach with named alternatives. Propose distinguishing AI that produces human-verified drafts from AI whose output is relied on directly, because the named author's reconciliation is itself a credibility control; propose PCCP-compatible lifecycle-monitoring language; and propose tiered disclosure that satisfies transparency without forcing commercial confidential information into the public record.
• Run public consultation as a managed capability, not a heroic one-off, with a named owner, docket monitoring, cross-functional drafting and legal review, and on-time filing with margin. FDA comments are filed via regulations.gov against a docket with a published deadline and become part of the citable public record, so nothing in a comment can expose confidential information. The EMA leans on written consultation responses and workshops, the MHRA AI Airlock publishes findings worth studying to anticipate controls, and ICH Step-2 carries the largest multiplier because one comment shapes the rule across every ICH region at once.
• Convert the comment into a coalition and close the loop back to the enterprise. Coordinate the organization's letter with the aggregated positions of DIA, RAPS, TransCelerate, PHUSE, and bodies like EFPIA so a reviewer sees the same concern echoed across voices, route every emerging evidentiary expectation into the validation framework before the guidance finalizes, and treat the engagement record as the asset that answers an inspector, a board, or a Day 74 IR. The leader who does this is one of the rule's authors, not its subject.